Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $12
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $7 to $12.
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $7 to $12.